A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia

The prognosis of chronic lymphocytic leukemia (CLL) patients displaying trisomy 12 (+12) remains unclear. In this study, we analyzed the influence of the proportion of cells with +12, and other clinical and biologic factors, in time to first therapy (TTFT) and overall survival (OS), in 289 patients...

Full description

Saved in:
Bibliographic Details
Published in:Hematological oncology 2016-06, Vol.34 (2), p.84-92
Main Authors: González-Gascón y Marín, Isabel, Hernández-Sánchez, María, Rodríguez-Vicente, Ana-Eugenia, Sanzo, Carmen, Aventín, Anna, Puiggros, Anna, Collado, Rosa, Heras, Cecilia, Muñoz, Carolina, Delgado, Julio, Ortega, Margarita, González, María-Teresa, Marugán, Isabel, de la Fuente, Ignacio, Recio, Isabel, Bosch, Francesc, Espinet, Blanca, González, Marcos, Hernández-Rivas, Jesús-María, Hernández, José-Ángel
Format: Article
Language:English
Subjects:
12
Adult
Aged
Aged, 80 and over
Chromosomes, Human, Pair 12 - genetics
chronic lymphocytic leukemia
Disease-Free Survival
Female
Humans
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell - blood
Leukemia, Lymphocytic, Chronic, B-Cell - genetics
Leukemia, Lymphocytic, Chronic, B-Cell - mortality
Leukemia, Lymphocytic, Chronic, B-Cell - therapy
Lymphocyte receptors
Male
Medical prognosis
Middle Aged
prognosis
Survival Rate
Trisomy - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The prognosis of chronic lymphocytic leukemia (CLL) patients displaying trisomy 12 (+12) remains unclear. In this study, we analyzed the influence of the proportion of cells with +12, and other clinical and biologic factors, in time to first therapy (TTFT) and overall survival (OS), in 289 patients diagnosed with CLL carrying +12. Median OS was 129 months. One hundred seventy‐four patients (60.2%) presented +12 in
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.2196